{"entity":{"type":"insider","cik":"0001825376","url":"/insider/0001825376","json_url":"/insider/0001825376.json","name":"RA Capital Nexus Fund II, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":87,"n_filings":41,"first":"2021-07-08","last":"2026-05-06","span_basis":"filed_date"},"name_variants":[{"name":"RA Capital Nexus Fund II, L.P.","source":"filing","n_filings":41,"first_seen":"2021-07-08","last_seen":"2026-05-06"}],"transactions":[{"id":5811518,"accession":"0001231919-26-000457","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001231919-26-000457","line_url":"/filing/0001231919-26-000457","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Hemab Therapeutics Holdings, Inc.","issuer_ticker":"COAG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; Kolchinsky Peter; RA Capital Nexus Fund IV, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":68018.0,"shares_display":"68,018","price_per_share":24.60230056749684,"price_display":"24.60","price_state":"stated","total_value":1673399.28,"total_display":"1,673,399.28","total_whole":"1,673,399","shares_owned_after":6314525.0,"shares_owned_after_display":"6,314,525","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-06","filed_date":"2026-05-06","scope":"insider","n_lines":2},{"id":5811512,"accession":"0001231919-26-000457","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001231919-26-000457","line_url":"/filing/0001231919-26-000457","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Hemab Therapeutics Holdings, Inc.","issuer_ticker":"COAG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; Kolchinsky Peter; RA Capital Nexus Fund IV, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":97411.0,"shares_display":"97,411","price_per_share":24.63321770641919,"price_display":"24.63","price_state":"stated","total_value":2399546.37,"total_display":"2,399,546.37","total_whole":"2,399,546","shares_owned_after":6236239.0,"shares_owned_after_display":"6,236,239","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-05","filed_date":"2026-05-06","scope":"insider","n_lines":2},{"id":5811508,"accession":"0001231919-26-000457","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001231919-26-000457","line_url":"/filing/0001231919-26-000457","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Hemab Therapeutics Holdings, Inc.","issuer_ticker":"COAG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; Kolchinsky Peter; RA Capital Nexus Fund IV, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Healthcare Fund LP","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2675000.0,"shares_display":"2,675,000","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":48150000.0,"total_display":"48,150,000.00","total_whole":"48,150,000","shares_owned_after":6149096.0,"shares_owned_after_display":"6,149,096","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-05-04","filed_date":"2026-05-06","scope":"insider","n_lines":2},{"id":5965432,"accession":"0001231919-26-000018","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-26-000018","line_url":"/filing/0001231919-26-000018#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Climb Bio, Inc.","issuer_ticker":"CLYM","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Nexus Fund III, L.P.; RA Capital Nexus Fund II, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7111.0,"shares_display":"7,111","price_per_share":3.5,"price_display":"3.50","price_state":"stated","total_value":24888.5,"total_display":"24,888.50","total_whole":"24,889","shares_owned_after":3403429.0,"shares_owned_after_display":"3,403,429","ownership_form":"I","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-07","scope":"insider"},{"id":4944278,"accession":"0001231919-25-000616","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001231919-25-000616","line_url":"/filing/0001231919-25-000616#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Climb Bio, Inc.","issuer_ticker":"CLYM","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.","owner_display_name":"RA Capital Nexus Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":101462.0,"shares_display":"101,462","price_per_share":2.86,"price_display":"2.86","price_state":"stated","total_value":290181.32,"total_display":"290,181.32","total_whole":"290,181","shares_owned_after":3396318.0,"shares_owned_after_display":"3,396,318","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-12","filed_date":"2025-12-15","scope":"insider"},{"id":4944274,"accession":"0001231919-25-000616","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001231919-25-000616","line_url":"/filing/0001231919-25-000616#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Climb Bio, Inc.","issuer_ticker":"CLYM","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund III, L.P.","owner_display_name":"RA Capital Nexus Fund, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":213099.0,"shares_display":"213,099","price_per_share":2.18,"price_display":"2.18","price_state":"stated","total_value":464555.82,"total_display":"464,555.82","total_whole":"464,556","shares_owned_after":3294856.0,"shares_owned_after_display":"3,294,856","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-12-11","filed_date":"2025-12-15","scope":"insider"},{"id":5120345,"accession":"0001231919-25-000265","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001231919-25-000265","line_url":"/filing/0001231919-25-000265#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"PepGen Inc.","issuer_ticker":"PEPG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9375000.0,"shares_display":"9,375,000","price_per_share":3.2,"price_display":"3.20","price_state":"stated","total_value":30000000.0,"total_display":"30,000,000.00","total_whole":"30,000,000","shares_owned_after":18554273.0,"shares_owned_after_display":"18,554,273","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-26","filed_date":"2025-09-30","scope":"insider"},{"id":4683651,"accession":"0001415889-25-012942","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-012942","line_url":"/filing/0001415889-25-012942#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":162539.0,"shares_display":"162,539","price_per_share":0.98,"price_display":"0.98","price_state":"stated","total_value":159288.22,"total_display":"159,288.22","total_whole":"159,288","shares_owned_after":6237482.0,"shares_owned_after_display":"6,237,482","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-14","filed_date":"2025-05-14","scope":"insider"},{"id":4683647,"accession":"0001415889-25-012942","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-012942","line_url":"/filing/0001415889-25-012942#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":52974.0,"shares_display":"52,974","price_per_share":0.98,"price_display":"0.98","price_state":"stated","total_value":51914.52,"total_display":"51,914.52","total_whole":"51,915","shares_owned_after":6074943.0,"shares_owned_after_display":"6,074,943","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-13","filed_date":"2025-05-14","scope":"insider"},{"id":4683641,"accession":"0001415889-25-012942","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-25-012942","line_url":"/filing/0001415889-25-012942#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Werewolf Therapeutics, Inc.","issuer_ticker":"HOWL","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":320913.0,"shares_display":"320,913","price_per_share":0.86,"price_display":"0.86","price_state":"stated","total_value":275985.18,"total_display":"275,985.18","total_whole":"275,985","shares_owned_after":6021969.0,"shares_owned_after_display":"6,021,969","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-05-12","filed_date":"2025-05-14","scope":"insider"},{"id":4589204,"accession":"0001415889-25-007443","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-007443","line_url":"/filing/0001415889-25-007443#line-4","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Janux Therapeutics, Inc.","issuer_ticker":"JANX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; Shah Rajeev M.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":110206.0,"shares_display":"110,206","price_per_share":31.02,"price_display":"31.02","price_state":"stated","total_value":3418590.12,"total_display":"3,418,590.12","total_whole":"3,418,590","shares_owned_after":10141287.0,"shares_owned_after_display":"10,141,287","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-07","filed_date":"2025-03-07","scope":"insider"},{"id":4589199,"accession":"0001415889-25-007443","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-25-007443","line_url":"/filing/0001415889-25-007443#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Janux Therapeutics, Inc.","issuer_ticker":"JANX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; Shah Rajeev M.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":372093.0,"shares_display":"372,093","price_per_share":30.78,"price_display":"30.78","price_state":"stated","total_value":11453022.54,"total_display":"11,453,022.54","total_whole":"11,453,023","shares_owned_after":10031081.0,"shares_owned_after_display":"10,031,081","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-06","filed_date":"2025-03-07","scope":"insider"},{"id":4589193,"accession":"0001415889-25-007443","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-007443","line_url":"/filing/0001415889-25-007443","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Janux Therapeutics, Inc.","issuer_ticker":"JANX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Kolchinsky Peter; Shah Rajeev M.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.","owner_display_name":"Kolchinsky Peter","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":341742.0,"shares_display":"341,742","price_per_share":30.641104166300895,"price_display":"30.64","price_state":"stated","total_value":10471352.22,"total_display":"10,471,352.22","total_whole":"10,471,352","shares_owned_after":9621533.0,"shares_owned_after_display":"9,621,533","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-03-05","filed_date":"2025-03-07","scope":"insider","n_lines":2},{"id":3143704,"accession":"0001415889-24-025502","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-025502","line_url":"/filing/0001415889-24-025502#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Janux Therapeutics, Inc.","issuer_ticker":"JANX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter; RA Capital Nexus Fund II, L.P.","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1200000.0,"shares_display":"1,200,000","price_per_share":44.75,"price_display":"44.75","price_state":"stated","total_value":53700000.0,"total_display":"53,700,000.00","total_whole":"53,700,000","shares_owned_after":9317246.0,"shares_owned_after_display":"9,317,246","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-18","filed_date":"2024-10-22","scope":"insider"},{"id":2070410,"accession":"0001415889-24-021199","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-021199","line_url":"/filing/0001415889-24-021199","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; Kolchinsky Peter; RA Capital Healthcare Fund LP; RA Capital Nexus Fund II, L.P.","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3525094.0,"shares_display":"3,525,094","price_per_share":1.08,"price_display":"1.08","price_state":"stated","total_value":3807101.52,"total_display":"3,807,101.52","total_whole":"3,807,102","shares_owned_after":1725348.0,"shares_owned_after_display":"1,725,348","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-08-09","filed_date":"2024-08-13","scope":"insider","n_lines":2},{"id":3054313,"accession":"0001415889-24-018708","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-018708","line_url":"/filing/0001415889-24-018708","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Eliem Therapeutics, Inc.","issuer_ticker":"ELYM","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; RA Capital Nexus Fund, L.P.; Kolchinsky Peter; RA Capital Nexus Fund III, L.P.; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":13008546.0,"shares_display":"13,008,546","price_per_share":3.84,"price_display":"3.84","price_state":"stated","total_value":49952816.64,"total_display":"49,952,816.64","total_whole":"49,952,817","shares_owned_after":23521757.0,"shares_owned_after_display":"23,521,757","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-06-27","filed_date":"2024-07-01","scope":"insider","n_lines":2},{"id":2278321,"accession":"0001415889-24-010278","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-010278","line_url":"/filing/0001415889-24-010278","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Boundless Bio, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":312500.0,"shares_display":"312,500","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":5000000.0,"total_display":"5,000,000.00","total_whole":"5,000,000","shares_owned_after":1884787.0,"shares_owned_after_display":"1,884,787","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-02","filed_date":"2024-04-04","scope":"insider","n_lines":2},{"id":2601748,"accession":"0001415889-24-009268","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-009268","line_url":"/filing/0001415889-24-009268#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter; RA Capital Nexus Fund II, L.P.","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":505954.0,"shares_display":"505,954","price_per_share":9.79,"price_display":"9.79","price_state":"stated","total_value":4953289.66,"total_display":"4,953,289.66","total_whole":"4,953,290","shares_owned_after":9958073.0,"shares_owned_after_display":"9,958,073","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-27","filed_date":"2024-03-27","scope":"insider"},{"id":2601742,"accession":"0001415889-24-009268","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-009268","line_url":"/filing/0001415889-24-009268#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter; RA Capital Nexus Fund II, L.P.","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":457745.0,"shares_display":"457,745","price_per_share":9.55,"price_display":"9.55","price_state":"stated","total_value":4371464.75,"total_display":"4,371,464.75","total_whole":"4,371,465","shares_owned_after":9452119.0,"shares_owned_after_display":"9,452,119","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-26","filed_date":"2024-03-27","scope":"insider"},{"id":2601734,"accession":"0001415889-24-009268","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-009268","line_url":"/filing/0001415889-24-009268#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter; RA Capital Nexus Fund II, L.P.","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":437600.0,"shares_display":"437,600","price_per_share":9.06,"price_display":"9.06","price_state":"stated","total_value":3964656.0,"total_display":"3,964,656.00","total_whole":"3,964,656","shares_owned_after":8994374.0,"shares_owned_after_display":"8,994,374","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-25","filed_date":"2024-03-27","scope":"insider"},{"id":3141232,"accession":"0001415889-24-009077","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-009077","line_url":"/filing/0001415889-24-009077","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stockj","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":998009.0,"shares_display":"998,009","price_per_share":15.03,"price_display":"15.03","price_state":"stated","total_value":15000075.27,"total_display":"15,000,075.27","total_whole":"15,000,075","shares_owned_after":694755.0,"shares_owned_after_display":"694,755","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-03-21","filed_date":"2024-03-25","scope":"insider","n_lines":2},{"id":2060123,"accession":"0001209191-24-003175","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-24-003175","line_url":"/filing/0001209191-24-003175#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"PepGen Inc.","issuer_ticker":"PEPG","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; RA CAPITAL MANAGEMENT, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2557593.0,"shares_display":"2,557,593","price_per_share":10.64,"price_display":"10.64","price_state":"stated","total_value":27212789.52,"total_display":"27,212,789.52","total_whole":"27,212,790","shares_owned_after":9179273.0,"shares_owned_after_display":"9,179,273","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-02-09","filed_date":"2024-02-13","scope":"insider"},{"id":7925265,"accession":"0001104659-23-103529","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-103529","line_url":"/filing/0001104659-23-103529","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; Kolchinsky Peter; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2700000.0,"shares_display":"2,700,000","price_per_share":3.0309354592592594,"price_display":"3.03","price_state":"stated","total_value":8183525.74,"total_display":"8,183,525.74","total_whole":"8,183,526","shares_owned_after":8365465.0,"shares_owned_after_display":"8,365,465","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-09-21","filed_date":"2023-09-25","scope":"insider","n_lines":2},{"id":8697655,"accession":"0001104659-23-097327","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-097327","line_url":"/filing/0001104659-23-097327#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"ARS Pharmaceuticals, Inc.","issuer_ticker":"SPRY","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Director","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3750000.0,"shares_display":"3,750,000","price_per_share":6.2,"price_display":"6.20","price_state":"stated","total_value":23250000.0,"total_display":"23,250,000.00","total_whole":"23,250,000","shares_owned_after":5856774.0,"shares_owned_after_display":"5,856,774","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-08-29","filed_date":"2023-08-31","scope":"insider"},{"id":7925170,"accession":"0001104659-23-094274","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-094274","line_url":"/filing/0001104659-23-094274#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1777778.0,"shares_display":"1,777,778","price_per_share":9.0,"price_display":"9.00","price_state":"stated","total_value":16000002.0,"total_display":"16,000,002.00","total_whole":"16,000,002","shares_owned_after":5135683.0,"shares_owned_after_display":"5,135,683","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-08-18","filed_date":"2023-08-22","scope":"insider"},{"id":8001213,"accession":"0001104659-23-083857","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-083857","line_url":"/filing/0001104659-23-083857#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Acumen Pharmaceuticals, Inc.","issuer_ticker":"ABOS","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Healthcare Fund LP; Shah Rajeev M.; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; RA CAPITAL MANAGEMENT, L.P.","owner_display_name":"RA Capital Healthcare Fund LP","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5161290.0,"shares_display":"5,161,290","price_per_share":7.75,"price_display":"7.75","price_state":"stated","total_value":39999997.5,"total_display":"39,999,997.50","total_whole":"39,999,998","shares_owned_after":13043179.0,"shares_owned_after_display":"13,043,179","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-21","filed_date":"2023-07-25","scope":"insider"},{"id":7925111,"accession":"0001104659-23-083069","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-083069","line_url":"/filing/0001104659-23-083069#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Janux Therapeutics, Inc.","issuer_ticker":"JANX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; Kolchinsky Peter; RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; RA Capital Nexus Fund II, L.P.","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":495008.0,"shares_display":"495,008","price_per_share":12.46,"price_display":"12.46","price_state":"stated","total_value":6167799.68,"total_display":"6,167,799.68","total_whole":"6,167,800","shares_owned_after":8117246.0,"shares_owned_after_display":"8,117,246","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-07-19","filed_date":"2023-07-21","scope":"insider"},{"id":8202369,"accession":"0001104659-23-039250","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-23-039250","line_url":"/filing/0001104659-23-039250#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"DICE Therapeutics, Inc.","issuer_ticker":"DICE","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":195997.0,"shares_display":"195,997","price_per_share":28.74,"price_display":"28.74","price_state":"stated","total_value":5632953.78,"total_display":"5,632,953.78","total_whole":"5,632,954","shares_owned_after":7070205.0,"shares_owned_after_display":"7,070,205","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-30","filed_date":"2023-03-30","scope":"insider"},{"id":8202365,"accession":"0001104659-23-039250","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-039250","line_url":"/filing/0001104659-23-039250#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"DICE Therapeutics, Inc.","issuer_ticker":"DICE","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":66369.0,"shares_display":"66,369","price_per_share":29.38,"price_display":"29.38","price_state":"stated","total_value":1949921.22,"total_display":"1,949,921.22","total_whole":"1,949,921","shares_owned_after":6874208.0,"shares_owned_after_display":"6,874,208","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-29","filed_date":"2023-03-30","scope":"insider"},{"id":8202360,"accession":"0001104659-23-039250","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-039250","line_url":"/filing/0001104659-23-039250#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"DICE Therapeutics, Inc.","issuer_ticker":"DICE","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":246779.0,"shares_display":"246,779","price_per_share":29.24,"price_display":"29.24","price_state":"stated","total_value":7215817.96,"total_display":"7,215,817.96","total_whole":"7,215,818","shares_owned_after":6807839.0,"shares_owned_after_display":"6,807,839","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-28","filed_date":"2023-03-30","scope":"insider"},{"id":8224437,"accession":"0001104659-23-037172","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-23-037172","line_url":"/filing/0001104659-23-037172#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"DICE Therapeutics, Inc.","issuer_ticker":"DICE","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund II, L.P.; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":151132.0,"shares_display":"151,132","price_per_share":27.48,"price_display":"27.48","price_state":"stated","total_value":4153107.36,"total_display":"4,153,107.36","total_whole":"4,153,107","shares_owned_after":6561060.0,"shares_owned_after_display":"6,561,060","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-27","filed_date":"2023-03-27","scope":"insider"},{"id":8224432,"accession":"0001104659-23-037172","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-23-037172","line_url":"/filing/0001104659-23-037172#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"DICE Therapeutics, Inc.","issuer_ticker":"DICE","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund II, L.P.; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":192335.0,"shares_display":"192,335","price_per_share":26.87,"price_display":"26.87","price_state":"stated","total_value":5168041.45,"total_display":"5,168,041.45","total_whole":"5,168,041","shares_owned_after":6409928.0,"shares_owned_after_display":"6,409,928","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-24","filed_date":"2023-03-27","scope":"insider"},{"id":8224422,"accession":"0001104659-23-037172","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-23-037172","line_url":"/filing/0001104659-23-037172#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"DICE Therapeutics, Inc.","issuer_ticker":"DICE","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Nexus Fund II, L.P.; RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":155089.0,"shares_display":"155,089","price_per_share":26.67,"price_display":"26.67","price_state":"stated","total_value":4136223.63,"total_display":"4,136,223.63","total_whole":"4,136,224","shares_owned_after":6217593.0,"shares_owned_after_display":"6,217,593","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-03-23","filed_date":"2023-03-27","scope":"insider"},{"id":6814780,"accession":"0001104659-22-120780","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-22-120780","line_url":"/filing/0001104659-22-120780#line-3","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"Acrivon Therapeutics, Inc.","issuer_ticker":"ACRV","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; RA Capital Nexus Fund II, L.P.; Shah Rajeev M.","owner_display_name":"RA CAPITAL MANAGEMENT, L.P.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3389500.0,"shares_display":"3,389,500","price_per_share":12.5,"price_display":"12.50","price_state":"stated","total_value":42368750.0,"total_display":"42,368,750.00","total_whole":"42,368,750","shares_owned_after":4384206.0,"shares_owned_after_display":"4,384,206","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-11-17","filed_date":"2022-11-21","scope":"insider"},{"id":6702257,"accession":"0001104659-22-110000","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-110000","line_url":"/filing/0001104659-22-110000#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"DICE Therapeutics, Inc.","issuer_ticker":"DICE","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"Shah Rajeev M.; RA Capital Healthcare Fund LP; RA CAPITAL MANAGEMENT, L.P.; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter","owner_display_name":"Shah Rajeev M.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1640000.0,"shares_display":"1,640,000","price_per_share":36.5,"price_display":"36.50","price_state":"stated","total_value":59860000.0,"total_display":"59,860,000.00","total_whole":"59,860,000","shares_owned_after":6848911.0,"shares_owned_after_display":"6,848,911","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-10-17","filed_date":"2022-10-19","scope":"insider"},{"id":6598078,"accession":"0001104659-22-086686","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-22-086686","line_url":"/filing/0001104659-22-086686#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA CAPITAL MANAGEMENT, L.P.; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA CAPITAL MANAGEMENT, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":100.0,"shares_display":"100","price_per_share":7.99,"price_display":"7.99","price_state":"stated","total_value":799.0,"total_display":"799.00","total_whole":"799","shares_owned_after":3773517.0,"shares_owned_after_display":"3,773,517","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-04","filed_date":"2022-08-05","scope":"insider"},{"id":6598075,"accession":"0001104659-22-086686","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-086686","line_url":"/filing/0001104659-22-086686#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA CAPITAL MANAGEMENT, L.P.; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA CAPITAL MANAGEMENT, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1809.0,"shares_display":"1,809","price_per_share":7.48,"price_display":"7.48","price_state":"stated","total_value":13531.32,"total_display":"13,531.32","total_whole":"13,531","shares_owned_after":3773417.0,"shares_owned_after_display":"3,773,417","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-03","filed_date":"2022-08-05","scope":"insider"},{"id":6476305,"accession":"0001104659-22-083728","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-22-083728","line_url":"/filing/0001104659-22-083728#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; RA CAPITAL MANAGEMENT, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8281.0,"shares_display":"8,281","price_per_share":7.91,"price_display":"7.91","price_state":"stated","total_value":65502.71,"total_display":"65,502.71","total_whole":"65,503","shares_owned_after":3771608.0,"shares_owned_after_display":"3,771,608","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-27","filed_date":"2022-07-28","scope":"insider"},{"id":6476302,"accession":"0001104659-22-083728","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-083728","line_url":"/filing/0001104659-22-083728#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA Capital Nexus Fund II, L.P.; RA CAPITAL MANAGEMENT, L.P.; Kolchinsky Peter; RA Capital Healthcare Fund LP; Shah Rajeev M.","owner_display_name":"RA Capital Nexus Fund II, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14938.0,"shares_display":"14,938","price_per_share":7.71,"price_display":"7.71","price_state":"stated","total_value":115171.98,"total_display":"115,171.98","total_whole":"115,172","shares_owned_after":3763327.0,"shares_owned_after_display":"3,763,327","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-26","filed_date":"2022-07-28","scope":"insider"},{"id":6124991,"accession":"0001104659-22-073920","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-073920","line_url":"/filing/0001104659-22-073920#line-1","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA CAPITAL MANAGEMENT, L.P.; Shah Rajeev M.; RA Capital Healthcare Fund LP; Kolchinsky Peter; RA Capital Nexus Fund II, L.P.","owner_display_name":"RA CAPITAL MANAGEMENT, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":302.0,"shares_display":"302","price_per_share":7.99,"price_display":"7.99","price_state":"stated","total_value":2412.98,"total_display":"2,412.98","total_whole":"2,413","shares_owned_after":3748389.0,"shares_owned_after_display":"3,748,389","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-21","filed_date":"2022-06-23","scope":"insider"},{"id":6247596,"accession":"0001104659-22-071465","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-22-071465","line_url":"/filing/0001104659-22-071465#line-2","is_derivative":false,"issuer_cik":"0001315082","issuer_name":"AN2 Therapeutics, Inc.","issuer_ticker":"ANTX","issuer_name_source":null,"issuer_url":"/issuer/0001315082","owner_cik":null,"owner_name":"RA CAPITAL MANAGEMENT, L.P.; RA Capital Nexus Fund II, L.P.; Kolchinsky Peter; Shah Rajeev M.; RA Capital Healthcare Fund LP","owner_display_name":"RA CAPITAL MANAGEMENT, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":61424.0,"shares_display":"61,424","price_per_share":7.9676,"price_display":"7.97","price_state":"stated","total_value":489401.8624,"total_display":"489,401.86","total_whole":"489,402","shares_owned_after":3748087.0,"shares_owned_after_display":"3,748,087","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-06-14","filed_date":"2022-06-15","scope":"insider"}],"collapsed":true,"next_cursor":"2022-06-14|6247596","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0002114044","name":"Hemab Therapeutics Holdings, Inc.","url":"/issuer/0002114044","role":"Director","n_filings":1,"first_seen":"2026-05-06","last_seen":"2026-05-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001768446","name":"Climb Bio, Inc.","url":"/issuer/0001768446","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2021-08-16","last_seen":"2026-01-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001835597","name":"PepGen Inc.","url":"/issuer/0001835597","role":"Director, Ten percent owner","n_filings":3,"first_seen":"2022-05-12","last_seen":"2025-09-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001785530","name":"Werewolf Therapeutics, Inc.","url":"/issuer/0001785530","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2025-05-14","last_seen":"2025-05-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001817713","name":"Janux Therapeutics, Inc.","url":"/issuer/0001817713","role":"Director","n_filings":3,"first_seen":"2023-07-21","last_seen":"2025-03-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001880438","name":"AN2 Therapeutics, Inc.","url":"/issuer/0001880438","role":"Ten percent owner","n_filings":7,"first_seen":"2022-03-31","last_seen":"2024-08-13"},{"type":"issuer","type_label":"ISSUER","cik":"0001782303","name":"Boundless Bio, Inc.","url":"/issuer/0001782303","role":"Ten percent owner","n_filings":1,"first_seen":"2024-04-04","last_seen":"2024-04-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001671858","name":"ARS Pharmaceuticals, Inc.","url":"/issuer/0001671858","role":"Director","n_filings":3,"first_seen":"2023-08-31","last_seen":"2024-03-27"},{"type":"issuer","type_label":"ISSUER","cik":"0001815776","name":"LENZ Therapeutics, Inc.","url":"/issuer/0001815776","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2024-03-25","last_seen":"2024-03-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001576885","name":"Acumen Pharmaceuticals, Inc.","url":"/issuer/0001576885","role":"Director","n_filings":2,"first_seen":"2021-07-08","last_seen":"2023-07-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001645569","name":"DICE Therapeutics, Inc.","url":"/issuer/0001645569","role":"Director, Ten percent owner","n_filings":4,"first_seen":"2021-09-20","last_seen":"2023-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001781174","name":"Acrivon Therapeutics, Inc.","url":"/issuer/0001781174","role":"Director, Ten percent owner","n_filings":1,"first_seen":"2022-11-21","last_seen":"2022-11-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001786255","name":"Icosavax, Inc.","url":"/issuer/0001786255","role":"Director, Ten percent owner","n_filings":2,"first_seen":"2021-08-04","last_seen":"2022-03-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001831915","name":"Cytek Biosciences, Inc.","url":"/issuer/0001831915","role":"Director","n_filings":8,"first_seen":"2021-07-29","last_seen":"2022-03-16"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001825376","retrieved_at":"2026-08-24T02:59:37+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}